Carrying out intended dosing regimens often require highly concentrated protein formulations that may be too viscous for subcutaneous administration or other routes of administration that are limited by volume. While reducing viscosity with a single excipient can be ineffective or compromising protein stability, our viscosity reduction platform of new excipient combinations offers a variety of manufacturing and final formulation benefits:
The result: subcutaneous administration of protein-based therapeutics to improve patient compliance and help avoid hospitalization.
Our viscosity reduction platform of new excipient combinations enables subcutaneous formulation of highly concentrated protein biologics, bringing together increased concentrations and improved downstream processing. As part of our industry leading Emprove® Program, all excipients are or will be made available in Emprove® Expert quality to support your clinical development and commercialization helping you to minimize regulatory and quality-associated risks.
|Product Number||Product Description|
|137118||L-Ornithine monohydrochloride EMPROVE® EXPERT DAB|
|107267||L-Phenylalanin EMPROVE® EXPERT Ph Eur,USP|
|500667||Thiamine phosphoric acid ester chloride dihydrate EMPROVE® API|